MEI Pharma Valuation
| MEIP Stock | USD 2.81 0.01 0.36% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. MEI Pharma secures a last-minute Real Value of $8.04 per share. The latest price of the firm is $2.81. Our model forecasts the value of MEI Pharma from evaluating the firm fundamentals such as profit margin of 0.27 %, and Return On Equity of 0.62 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting MEI Pharma's valuation include:
Price Book 0.766 | Enterprise Value -19.3 M | Enterprise Value Ebitda (1.58) | Price Sales 0.2857 | Enterprise Value Revenue 1.3924 |
Undervalued
Today
Please note that MEI Pharma's price fluctuation is somewhat reliable at this time. Calculation of the real value of MEI Pharma is based on 3 months time horizon. Increasing MEI Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
MEI Pharma's intrinsic value may or may not be the same as its current market price of 2.81, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.81 | Real 8.04 | Target 23.67 | Hype 2.81 | Naive 2.55 |
The intrinsic value of MEI Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence MEI Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of MEI Pharma helps investors to forecast how MEI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MEI Pharma more accurately as focusing exclusively on MEI Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use MEI Pharma's intrinsic value based on its ongoing forecasts of MEI Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against MEI Pharma's closest peers.
MEI Pharma Cash |
|
MEI Valuation Trend
MEI Pharma's real value is important for investors to make better decisions and a more accurate overall view of MEI Pharma's financial worth over time. Using both MEI Pharma's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
MEI Pharma Total Value Analysis
MEI Pharma is now forecasted to have valuation of (19.29 M) with market capitalization of 18.66 M, debt of 8.36 M, and cash on hands of 153.25 M. The negative valuation of MEI Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the MEI Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(19.29 M) | 18.66 M | 8.36 M | 153.25 M |
MEI Pharma Investor Information
About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MEI Pharma recorded a loss per share of 6.99. The entity last dividend was issued on the 16th of November 2023. The firm had 1:20 split on the 17th of April 2023. Based on the key measurements obtained from MEI Pharma's financial statements, MEI Pharma is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in December.MEI Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. MEI Pharma has an asset utilization ratio of 157.82 percent. This connotes that the Company is making $1.58 for each dollar of assets. An increasing asset utilization means that MEI Pharma is more efficient with each dollar of assets it utilizes for everyday operations.MEI Pharma Ownership Allocation
The market capitalization of MEI Pharma is $18.66 Million. 30% of MEI Pharma outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thus, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.MEI Pharma Profitability Analysis
The company reported the previous year's revenue of 65.3 M. Net Income was 17.78 M with profit before overhead, payroll, taxes, and interest of 48.82 M.MEI Pharma Past Distributions to stockholders
About MEI Pharma Valuation
The stock valuation mechanism determines MEI Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of MEI Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of MEI Pharma. We calculate exposure to MEI Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MEI Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 49.3 M | 51.8 M | |
| Pretax Profit Margin | 0.27 | 0.29 | |
| Operating Profit Margin | 0.22 | 0.23 | |
| Net Profit Margin | 0.27 | 0.29 | |
| Gross Profit Margin | 0.76 | 0.79 |
A single share of MEI Pharma represents a small ownership stake in the entity. As a stockholder of MEI, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
MEI Pharma Dividends Analysis For Valuation
Please note that MEI Pharma has scaled down on payment of dividends at this time. At this time, MEI Pharma's Earnings Yield is relatively stable compared to the past year. As of 11/22/2024, Price Earnings Ratio is likely to grow to 1.12, though Retained Earnings are likely to grow to (368.8 M).
There are various types of dividends MEI Pharma can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of MEI shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from MEI Pharma directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When MEI pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of MEI Pharma by the value of the dividends paid out.
MEI Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as MEI Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.7 M |
MEI Pharma Current Valuation Indicators
MEI Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final MEI Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as MEI Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use MEI Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes MEI Pharma's worth.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.